Last updated: May 25, 2026
Climara (estradiol transdermal system) suppliers: who makes the product, APIs, and key packaging components?
Climara is an estradiol transdermal product supplied via branded manufacturing and supply-chain partners that support (1) estradiol drug substance (API) sourcing, (2) transdermal system manufacturing (drug-in-adhesive and backing/liner assembly), and (3) packaging and distribution. Supplier identification depends on the specific Climara strength and the national drug-distribution channel; without confirmed lot-level manufacturer details and current listing from the FDA’s Drug Registration and Listing System or the Orange Book product record for the specific strength, supplier mapping cannot be completed accurately.
What suppliers make Climara estradiol transdermal systems (10, 20, 25 mcg)?
No complete, accurate supplier roster can be produced from the information provided. A Climara “supplier” list must be anchored to the exact marketed strengths and their corresponding labeled manufacturer(s), which are product- and strength-specific.
Which company names appear on the Climara label for each strength?
- Labeled manufacturer and distributor vary by strength and distribution channel.
- For supplier-grade accuracy, the supplier names must match:
- the labeled “manufactured for” entity, and
- the listed NDA product manufacturer(s) in the FDA Orange Book record for the specific strength.
What patents protect Climara, and do they constrain supplier options?
Climara’s patent estate can constrain “drop-in” supplier entry because transdermal systems depend on formulation, adhesive composition, membrane/backing design, and manufacturing method claims. Supplier availability is limited to companies that either:
- hold the relevant rights, or
- use design-around formulations and manufacturing processes that avoid infringement.
How many patents cover Climara transdermal technology?
A quantified count requires the specific reference product record and its listed patents (Orange Book patent families by application/strength). That data is not provided.
Which formulations are protected by Climara patents?
Transdermal systems can be protected by:
- adhesive matrix composition,
- estradiol load and release-rate control,
- backing/liner material structures,
- manufacturing method steps.
A claim-to-supplier mapping requires the exact patent list and claim scope, which is not provided.
What is the Orange Book status of Climara for generics and authorized suppliers?
Orange Book status is strength-specific and can change with:
- patent listing updates,
- 505(b)(2) pathway submissions,
- changes in manufacturer listings.
A precise Orange Book status and eligibility for generic supply cannot be stated without the referenced Orange Book product record for Climara.
When does Climara lose exclusivity, and what does that mean for new suppliers?
Exclusivity and patent expiration dates drive supplier risk and entry timing. Without:
- the NDA number tied to each Climara strength,
- the Orange Book listed expiration and exclusivity fields,
- any relevant pediatric exclusivity or other time extensions,
a correct exclusivity timeline cannot be produced.
What generic entry risks exist for Climara, and who supplies competitors?
Generic and authorized generic entry risks for Climara depend on:
- patent carve-outs and Paragraph IV challenges,
- settlement terms,
- FDA approval timelines,
- transdermal system bioequivalence and manufacturing compliance.
A competitor supplier landscape cannot be built without the generic/ANDA roster for the Climara strengths.
Which companies are challenging Climara patents via ANDA Paragraph IV?
Paragraph IV challenger identification is sourced from FDA litigation databases and court records tied to specific patent numbers. No patent identifiers or case list are provided, so challenger names cannot be stated.
What FDA regulatory approvals govern Climara manufacturing and supplier qualification?
Transdermal systems require:
- cGMP manufacturing in approved facilities,
- validated formulation and release specifications,
- FDA inspection readiness for both drug product and, where applicable, drug substance.
A list of qualifying manufacturing sites and the responsible regulatory entities must be grounded in:
- FDA establishment listings,
- Orange Book application records, and
- NDA holder/manufacturer details.
That dataset is not provided.
How does Climara compare with other estradiol patches for supplier sourcing?
Supplier sourcing differs by product technology:
- reservoir vs matrix patches,
- different adhesive/backing systems,
- different release kinetics,
- different manufacturing method claims.
A supplier comparison requires specific competitor product records (e.g., other estradiol transdermal patch brands) and their labeled manufacturing entities.
Key takeaways
- A reliable “suppliers for Climara” list must be tied to exact strength-specific label/manufacturer entities and FDA-listed manufacturing details.
- No Orange Book product record, NDA number, labeled manufacturer, or strength mapping is provided, so a complete supplier roster cannot be produced without risking material inaccuracies.
FAQs
- Who is the NDA holder or marketing authorization holder for Climara?
- Which manufacturing facilities make Climara transdermal systems for each strength?
- Are estradiol APIs for Climara sourced from multiple qualified vendors?
- What transdermal technologies (matrix vs reservoir) are used for Climara and who supplies them?
- Do Climara patent listings restrict contract manufacturers from producing equivalents?
References
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-05-25).
- U.S. Food and Drug Administration. Drugs@FDA. (Accessed 2026-05-25).
